MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo data for investigational oral OPK-88006 tablet treatment has been selected for presentation at the ENDO 2025 annual meeting of the Endocrine Society, taking place July 12-15, 2025 in San Francisco, CA, USA. Oral OPK-88006 is being developed pursuant to a collaboration and license agreement between OPKO and Ente ...

MBX Biosciences (MBX) 2025 Conference June 04, 2025 02:00 PM ET Speaker0 Right. Good afternoon, everyone. Thank you Speaker1 for joining us on our next session. I'm Michael Yee, a biotechnology analyst at Jefferies. I am really pleased to have members of the team from MBX here with us, CEO Kent Harlock, as well as CMO Sam Azole. And importantly, the company is going Speaker0 to give a brief overview Speaker1 of what's going on at MBX. And obviously, I'm very excited about the upcoming data in the third quar ...